I am a graduate of Industrial and Business Service Management. I have been investing and writing about biotechnology stocks for many years now and have extensive experience writing about the science and companies themselves. I am a contributor to
more I am a graduate of Industrial and Business Service Management. I have been investing and writing about biotechnology stocks for many years now and have extensive experience writing about the science and companies themselves. I am a contributor to
TalkMarkets and
Seeking Alpha. You can also follow me on
Stocktwits or
Twitter. I look for Pharmaceutical companies that are bringing new science to life that will be able to treat a variety of today's diseases and in which patients don't have many options. I look for the innovation of new drug compounds.
less
Latest Comments
Goldman Tells Clients To Short Gold 5 Days After Saying Gold May Soar "Much Higher Over Time"
Of course this is Goldman Sachs you are talking about. They told clients to buy mortgage house backed securities during the financial crisis. On the flip side they were betting against those investments they sold to investors - 100% short. Doesn't surprise me they are doing this again.
Incyte Announces Discontinuation Of Pancreatic Cancer Trial
But they are successful in many types of blood cancer. Many successful biotechs target blood cancer only and do well. For instance PCYC only targets B-cell lymphoma and that got bought out. Incyte will be fine if other blood cancer trials are successful
Shares Of Chimerix, Inc. Tumble 80% After Phase 3 Clinical Trial Failure
There might be a chance for a recover in one of the other indications but considering the drug failed in a phase 3 trial the chance for success in the other indications is much smaller. It still might be possible but the chance % just went down greatly.
VIX-Selling Scramble, Crude-Buying Panic Sends S&P Green For 2015 (For Now)
Crude oil looks like its going to tumble further, no bottom in sight.
Bearish Apple Inc. Analyst Fired
I think every other analyst is in denial. It's too bad that honesty is not appreciated on Wall Street. I mean Apple is a strong company but he was right on with his prediction of the stock price. So many analysts have been calling for $140 per share for awhile and yet it remains at $108 per share, it can't even break $110. Too bad he got fired for being honest.
Activision's Black Ops Another Winner
Black Ops will sell very well like it always does in the Franchise so Activision is fine there.
Eli Lilly Scraps Major Cholesterol-Inhibitor Drug; Shares Fall 7.7%
The Lilly's Diabetes results look good, so that may help in the long run, but short-term it will probably fall some more. Analyst's will probably revalue their price targets as well.
Eli Lilly Scraps Major Cholesterol-Inhibitor Drug; Shares Fall 7.7%
short term it may decrease a little more. As I mentioned above their Alzheimer's is still a big "if" and their diabetes program might help the share price recover. But those aren't guaranteed though, keep that in mind.
Eli Lilly Scraps Major Cholesterol-Inhibitor Drug; Shares Fall 7.7%
The thing is that the pipeline is still if. Meaning there is a chance if the Diabetes is successful, and the Alzheimer's still needs to prove itself with final phase 3 results. There is not doubt though this was a $5 billion setback for sure. Which is probably why analysts had set their targets higher.
That's not to say its not a possible buy. But that all depends on the future Alzheimer results which is hard indication to target. If Eli Lilly gets it diabetes right then it still has a chance as well. Too many "Ifs" still involved.
S&P Futures Tumble 1.5% At Open: ES Down 33, Brent Under $60
Prepare for a bloody red Monday now as the Greek "No" vote will cause panic and fear in the markets.